Madrigal Pharmaceuticals (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which has completed Phase I single and multiple dose trials, an orally administered and small-molecule liver-directed selective thyroid hormone receptor-beta agonist for use in the treatment of nonalcoholic steatohepatitis (NASH), and heterozygous and homozygous familial hypercholesterolemia (FH) to lower LDL cholesterol, triglyceride levels, and Lp(a). For more information, visit the company’s website at www.madrigalpharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
